MoneyWorks4Me

Hind Bio Science - Quaterly Results

31 Jul 2023 Evaluate
A slight decline in the revenue of Rs. 0.00 millions was seen for the June 2023 quarter as against Rs. 2.71 millions during year-ago period.The Net Loss for the quarter ended June 2023 is Rs. -1.22 millions as compared to Net Loss of Rs. -0.25 millions of corresponding quarter ended June 2022 Operating profit Margin for the quarter ended June 2023 further decreased to -1.20% as compared to -0.24% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 0.00 2.71 0.00 0.00 2.71 0.00 9.22 4.31 113.92
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT -1.20 -0.24 400.00 -1.20 -0.24 400.00 -0.28 -5.06 -94.47
Interest 0.01 0.00 0.00 0.01 0.00 0.00 0.04 0.05 -20.00
PBDT -1.21 -0.24 404.17 -1.21 -0.24 404.17 -0.32 -5.11 -93.74
Depreciation 0.01 0.01 0.00 0.01 0.01 0.00 0.06 0.03 100.00
PBT -1.22 -0.25 388.00 -1.22 -0.25 388.00 -0.38 -5.14 -92.61
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 -33.33
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 -33.33
PAT -1.22 -0.25 388.00 -1.22 -0.25 388.00 -0.40 -5.17 -92.26
Equity 20.50 102.51 -80.00 20.50 102.51 -80.00 20.50 102.51 -80.00
PBIDTM(%) 0.00 -8.86 0.00 0.00 -8.86 0.00 -3.04 -117.40 -97.41
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..